Released: 11/10/2019 – 09:12 GMT
RNS Number: 6035P
In reference to the recent press releases regarding the entry of a new minority shareholder, Kedrion SpA confirms that there are pending negotiations but without any finalized agreement.
The entry of a new partner would be consistent with the development strategy that the Group is pursuing at a national and international level.
Should the transaction occur, the same will be subject to the approval of the competent Antitrust authorities.
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.
Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,500 employees and a commercial presence in approximately 100 countries worldwide.
Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Additional information about Kedrion can be found at kedrion.com